Verona Pharma PLC (VRNA)

NASDAQ: VRNA · IEX Real-Time Price · USD
4.40
0.22 (5.26%)
May 25, 2022 4:30 PM EDT - Market closed
Market Cap265.62M
Revenue (ttm)40.00M
Net Income (ttm)-59.12M
Shares Out60.37M
EPS (ttm)-0.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,752
Open4.13
Previous Close4.18
Day's Range4.06 - 4.40
52-Week Range3.41 - 7.87
Beta0.67
AnalystsBuy
Price Target21.42 (+386.8%)
Earnings DateMay 3, 2022

About VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing en...

IndustryPharmaceuticals
IPO DateApr 27, 2017
CEODavid Zaccardelli
Employees24
Stock ExchangeNASDAQ
Ticker SymbolVRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for VRNA stock is "Buy." The 12-month stock price forecast is 21.42, which is an increase of 386.82% from the latest price.

Price Target
$21.42
(386.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Verona Pharma to Present at Jefferies Healthcare Conference

LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company ov...

1 day ago - GlobeNewsWire

Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at...

Abstract supports ongoing Phase 3 program and planned NDA submission Abstract supports ongoing Phase 3 program and planned NDA submission

2 weeks ago - GlobeNewsWire

Verona Pharma Announces May 2022 Investor Conference Participation

LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:

3 weeks ago - GlobeNewsWire

Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022

3 weeks ago - GlobeNewsWire

Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces tha...

1 month ago - GlobeNewsWire

James Brady Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr....

2 months ago - GlobeNewsWire

Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 ENHANCE program on track to report top-line COPD data in 2022

2 months ago - GlobeNewsWire

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

3 months ago - GlobeNewsWire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line Data Expected in the Third Quarter of 2022 Top-line Data Expected in the Third Quarter of 2022

4 months ago - GlobeNewsWire

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022

4 months ago - GlobeNewsWire

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

4 months ago - GlobeNewsWire

Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction

Study Supports Ongoing Phase 3 Program and Planned NDA Submission Study Supports Ongoing Phase 3 Program and Planned NDA Submission

5 months ago - GlobeNewsWire

Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enrollment in ENHANCE-1 48-week subset and ENHANCE-2  expected to complete around year-end 2021

6 months ago - GlobeNewsWire

Verona Pharma Announces November 2021 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

6 months ago - GlobeNewsWire

Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

7 months ago - GlobeNewsWire

Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021

Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations

7 months ago - GlobeNewsWire

Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congr...

Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacok...

8 months ago - GlobeNewsWire

Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

8 months ago - GlobeNewsWire

Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

ENHANCE Phase 3 program on track to report top-line data in 2022

9 months ago - GlobeNewsWire

Verona Pharma Announces August 2021 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

9 months ago - GlobeNewsWire

Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

10 months ago - GlobeNewsWire

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that ...

1 year ago - GlobeNewsWire

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2...

Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its poten...

1 year ago - GlobeNewsWire

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

ENHANCE Phase 3 program enrollment continues on track to complete in 2H21

1 year ago - GlobeNewsWire

Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces dat...

1 year ago - GlobeNewsWire